- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05428462
Effectiveness of a One-day Psychoeducation Program on Internalized Stigmatization for BPD Patients (EDUC-BPD)
Effectiveness of a One-day Psychoeducation Program on Internalized Stigmatization for Borderline Personality Disorder (BPD) Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Borderline personality disorder defined as "a pattern of instability in interpersonal relationships, self-image and affects, and impulsiveness marked" concerns 4-6% of the general population. This is the emotional trouble the most associated with the occurence of suicide attempts (85% of these patients make multiple suicide attempts) and death by suicide (10% of these patients). This is a major public health problem.
A large number of patients with borderline personality disorder are not informed of their diagnosis. The main reasons are : the non-recognition of this disorder by health professionals, the belief that borderline personality disorder is a overly stigmatizing diagnosis , or preference to diagnose another disorder - that professionals think respond better to treatments and therefore be of a better prognosis.
Patients with borderline personality disorder often think themselves as "bad people" or the only people suffering from these symptoms. Thus, the ignorance of borderline personality disorder by patients leads to a basis of their altered sense of identity, perceived as defective or isolated. This generate a strong internalized stigma.
Many people diagnosed with borderline personality disorder receive no information about this disorder while psychoeducation has shown its effectiveness in severe psychiatric disorders, including the disorder of borderline personality, by reducing the negative repercussions psychiatric pathology. Moreover, the education of patients suffering from self-stigma makes it possible to in the face of negative beliefs around the disease and the acquisition of knowledge about the disorder and how to deal with it reduces self-stigma in bipolar patients. However, the propensity to feel shame - the stigmatization of oneself as worthless - is strongest in borderline personality disorder compared to all psychiatric disorders and most associated with the occurence of suicidal behaviors. In recommendations with good clinical practice, the investigator propose within the sector a day of education on borderline personality disorder including a transmission of current scientific knowledge on the illness, a dimensional understanding of the disorder, and the dis-identification of self to the symptoms of borderline personality disorder. The investigator hypothesize that this day of psychoeducation makes it possible to decrease self-stigma, which could be a mediator in reducing negative repercussions of borderline pathology.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34000
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with Borderline Personality disorder assessed according to SCID II
- Having attended the borderline education day
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of internalized stigma of mental illnessillness
Time Frame: At immediate post-intervention
|
Comparison of internalized stigma of mental illness between pre-treatment
|
At immediate post-intervention
|
Comparison of internalized stigma of mentalillness
Time Frame: At 3 months post-intervention
|
Comparison of internalized stigma of mental illness between pre-treatment
|
At 3 months post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depressive symptoms using the Beck Depression Inventory
Time Frame: At immediate post-intervention
|
Comparison of depressive symptoms between pre-treatment and post-intervention
|
At immediate post-intervention
|
Depressive symptoms using the Beck Depression Inventory
Time Frame: At 3 months post-intervention
|
Comparison of depressive symptoms between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Severity of suicidal ideation evaluated by the likert scales from 0 (none) to 10 (maximum possible suicidal ideation)
Time Frame: At immediate post-intervention
|
Comparison of the intensity of suicidal ideation between pre-treatment and post-intervention
|
At immediate post-intervention
|
Severity of suicidal ideation evaluated by the likert scales from 0 (none) to 10 (maximum possible suicidal ideation)
Time Frame: At 3 months post-intervention
|
Comparison of the intensity of suicidal ideation between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Psychological pain using the Likert scales from 0 (none) to 10 (maximum possible pain)
Time Frame: At immediate post-intervention
|
Comparison of psychological pain between pre-treatment and post-intervention
|
At immediate post-intervention
|
Psychological pain using the Likert scales from 0 (none) to 10 (maximum possible pain)
Time Frame: At 3 months post-intervention
|
Comparison of psychological pain between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
The intensity of hopelessness using the Likert scales from 0 (none) to 10 (maximum possible hopelessness)
Time Frame: At immediate post-intervention
|
Comparison of the intensity of hopelessness between pre-treatment and post-intervention
|
At immediate post-intervention
|
The intensity of hopelessness using the Likert scales from 0 (none) to 10 (maximum possible hopelessness)
Time Frame: At 3 months post-intervention
|
Comparison of the intensity of hopelessness between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
The intensity of optimism using analog visual scale
Time Frame: At immediate post-intervention
|
Comparison of the intensity of optimism between pre-treatment and post-intervention
|
At immediate post-intervention
|
The intensity of optimism using analog visual scale
Time Frame: At 3 months post-intervention
|
Comparison of the intensity of optimism between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Feeling of pleasure using the quality of life questionnaire on pleasure and satisfaction
Time Frame: At immediate post-intervention
|
Comparison of feeling of pleasure between pre-treatment and post-intervention
|
At immediate post-intervention
|
Feeling of pleasure using the quality of life questionnaire on pleasure and satisfaction
Time Frame: At 3 months post-intervention
|
Comparison of feeling of pleasure between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Feeling of satisfaction using the quality of life questionnaire on pleasure and satisfaction
Time Frame: At immediate post-intervention
|
Comparison of feeling of satisfaction between pre-treatment and post-intervention
|
At immediate post-intervention
|
Feeling of satisfaction using the quality of life questionnaire on pleasure and satisfaction
Time Frame: At 3 months post-intervention
|
Comparison of feeling of satisfaction between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Anxiety state using the State-Trait Inventory (STAI-State)
Time Frame: At immediate post-intervention
|
Comparison of the state of anxiety between pre-treatment and post-intervention
|
At immediate post-intervention
|
Anxiety state using the State-Trait Inventory (STAI-State)
Time Frame: At 3 months post-intervention
|
Comparison of the state of anxiety between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Hopelessness using the Beck Hopelessness Scale (BHS)
Time Frame: At immediate post-intervention
|
Comparison of the hopelessness between pre-treatment and post-intervention
|
At immediate post-intervention
|
Hopelessness using the Beck Hopelessness Scale (BHS)
Time Frame: At 3 months post-intervention
|
Comparison of the hopelessness between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Level of positive and negative affects using the PANAS Scale
Time Frame: At immediate post-intervention
|
Comparison of level of positive and negative affects between pre-treatment and post-intervention
|
At immediate post-intervention
|
Level of positive and negative affects using the PANAS Scale
Time Frame: At 3 months post-intervention
|
Comparison of level of positive and negative affects between pre-treatment and 3 months post-intervention
|
At 3 months post-intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL21_0611
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University of EdinburghRecruitingEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Silvia Elisa Hurtado SantiagoCompletedPersonality Disorder, BorderlineSpain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Universitat Jaume IHospital de la RiberaRecruitingBorderline Personality Disorder (BPD)Spain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
-
Rutgers, The State University of New JerseyActive, not recruitingBorderline Personality Disorder in AdolescenceUnited States
Clinical Trials on Psychoeducation day on borderline personality disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Freie Universität BerlinRuhr University of Bochum; University of BremenRecruitingBorderline Personality Disorder | MothersGermany
-
Centre for Addiction and Mental HealthEnrolling by invitationBorderline Personality Disorder | Suicide and Self-harmCanada
-
Dr Cipto Mangunkusumo General HospitalIndonesia UniversityCompleted
-
Shalvata Mental Health CenterUnknownBorderline Personality DisorderIsrael
-
BioMarin PharmaceuticalCompletedHypertensionUnited States
-
Radboud University Medical CenterBill and Melinda Gates FoundationCompleted
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)WithdrawnExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States